349 related articles for article (PubMed ID: 15584937)
1. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Silva MA; Gandhi PJ
J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
[TBL] [Abstract][Full Text] [Related]
2. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
3. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
4. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
5. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
6. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
[TBL] [Abstract][Full Text] [Related]
7. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
[No Abstract] [Full Text] [Related]
8. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Cannon CP
Clin Cardiol; 1999 Aug; 22(8 Suppl):IV30-6. PubMed ID: 10492851
[TBL] [Abstract][Full Text] [Related]
9. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Roe MT; Sapp SK; Lincoff AM
Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
[TBL] [Abstract][Full Text] [Related]
10. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Subbarao VD; Phillips J; Stouffer GA
Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570
[TBL] [Abstract][Full Text] [Related]
11. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Harrington RA
Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244
[TBL] [Abstract][Full Text] [Related]
12. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
Fintel DJ; Ledley GS
Clin Cardiol; 2000 Sep; 23 Suppl 5(Suppl 5):V1-12. PubMed ID: 11019716
[TBL] [Abstract][Full Text] [Related]
14. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
Campbell KR; Ohman EM; Cantor W; Lincoff AM
Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
McClure MW; Berkowitz SD; Sparapani R; Tuttle R; Kleiman NS; Berdan LG; Lincoff AM; Deckers J; Diaz R; Karsch KR; Gretler D; Kitt M; Simoons M; Topol EJ; Califf RM; Harrington RA
Circulation; 1999 Jun; 99(22):2892-900. PubMed ID: 10359733
[TBL] [Abstract][Full Text] [Related]
16. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
Tcheng JE
Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231
[No Abstract] [Full Text] [Related]
17. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ; Théroux P; Snapinn SM; Sax FL
Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
[TBL] [Abstract][Full Text] [Related]
18. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Harrington RA
Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233
[TBL] [Abstract][Full Text] [Related]
19. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
[No Abstract] [Full Text] [Related]
20. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
